Clinical trials: Patient-Centered Care
Non-Small-Cell Lung Carcinoma NSCLC
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the…
- Trial name
- MYSTIC (NCT02453282)
- Testing
- MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin
- Where
- 196 sites in United States, Australia and 15 more
- Volunteers
- 1,118 people
- Sponsor
- AstraZeneca
Lower Respiratory Tract Infection
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
This is a Prospective, multi-center study enrolling adults subjects presented to the ED/Urgent care, with symptoms consistent with lower respiratory infection (LRTI).
- Trial name
- NCT05762302
- Testing
- MeMed BV test
- Where
- 10 sites in United States, Israel
- Volunteers
- 1,316 people
- Sponsor
- MeMed Diagnostics Ltd.
Alzheimer Disease
Masitinib in Patients With Mild Alzheimer's Disease
Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia).
- Trial name
- NCT05564169
- Testing
- Masitinib (4.5), Standard of care
- Where
- 9 sites in France, Spain
- Volunteers
- 600 people
- Sponsor
- AB Science
Diabetic Foot Ulcer, Pressure Injury
A Dual-center Study Evaluating Clinical Acceptance of a NPWT Wound Care System
The purpose of this study is to determine if use of the Medela Invia Motion NPWT system supports acceptable progress towards the goal of therapy when treating patients with a variety of wound types during the evaluation period.
- Conditions
- Diabetic Foot Ulcer, Pressure Injury, Pressure Ulcer, Surgical Wound
- Trial name
- NCT04593693
- Testing
- Invia Motion Endure NPWT system
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Medela AG
Stroke
An Evaluation of Non-invasive ICP Monitoring in Patients Undergoing Routine Care
The HS-1000 device, an investigational intracranial monitoring device, has the potential to safely and quickly diagnose and assess stroke (and potentially other neurologic conditions) with minimal discomfort to patients.
- Trial name
- NCT02772484
- Testing
- HS-1000
- Where
- Armenia
- Volunteers
- 24 people
- Sponsor
- HeadSense Medical
Schizophrenia, Psychotic Disorders
Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection
The purpose of this study is to assess the usefulness of the Risperdal® Consta® Treatment Guidebook in helping the doctor switch the adult patient from taking risperidone tablets daily by mouth to taking long-acting risperidone…
- Trial name
- NCT00236548
- Testing
- risperidone
- Volunteers
- 1 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sedation
A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation
This is a multi-center, open-label, randomized, propofol-controlled phase II clinical trial.A total of ICU patients undergoing mechanical ventilation are intended to be enrolled and randomly assigned to HSK3486 group and propofol…
- Trial name
- NCT04147416
- Testing
- HSK3486 0.1-0.2 /0.3 mg / kg group, Propofol 0.5-1.0/1.5 mg/kg group
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Hypertension
Effects of Telemonitoring and Telemedicine Service for Hypertensive Care
This is a multi-centered, randomized, parallel group, interventional \& open label clinical trial accessing efficacy of intervention effect by smart care system over existing treatment group for lowering blood pressure of…
- Trial name
- Smart-HTN (NCT01335984)
- Testing
- Telemonitoring, Telemonitoring & Telemedicine, control group
- Where
- 3 sites in South Korea
- Volunteers
- 440 people
- Sponsor
- Chang Hee, Lee
Non Small Cell Lung Carcinoma NSCLC
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of…
- Trial name
- NEPTUNE (NCT02542293)
- Testing
- Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin
- Where
- 210 sites in United States, Argentina and 27 more
- Volunteers
- 953 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer, EGFR Gene Mutation
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
The first-line treatment with single agent AZD3759 results in superior Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with…
- Conditions
- Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases
- Trial name
- BM (NCT03653546)
- Testing
- AZD3759, Erlotinib, Gefitinib
- Where
- 58 sites in China, Singapore and 2 more
- Volunteers
- 492 people
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Alzheimer Disease
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD.
- Trial name
- NCT06566170
- Testing
- Donanemab, Usual Care
- Where
- United States
- Volunteers
- 6,250 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Hepatocellular
Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
This is a multi-centre, phase II study to assess the efficacy and safety of ZD6474 in patients with Child-Pugh class A, inoperable HCC. This study comprises 2 phases, the primary treatment phase and the secondary treatment phase.
- Trial name
- NCT00508001
- Testing
- Vandetanib, Best Supportive Care
- Where
- 3 sites in Taiwan
- Volunteers
- 67 people
- Sponsor
- Genzyme, a Sanofi Company
Glioblastoma Multiforme, Glioblastoma
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult, Glioma
- Trial name
- NCT06496971
- Testing
- Bevacizumab, Microbubble, Low-Intensity Focused Ultrasound
- Where
- 2 sites in Taiwan
- Volunteers
- 32 people
- Sponsor
- NaviFUS Corporation
Ulcerative Colitis
Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)
To evaluate the percentage of subjects with clinical recurrence of UC at 6 months using MMX mesalamine once daily.
- Trial name
- NCT00446849
- Testing
- MMX Mesalamine
- Where
- 62 sites in United States
- Volunteers
- 290 people
- Sponsor
- Shire
Brain Injuries
Point-Of-Care TBI Detection System For Head Injured Patients In The Emergency Department
A prospective, non-randomized trial for the extension and replication of the development database of brain electrical activity recordings and clinical information collected from patients who present to the ED following closed…
- Trial name
- READ-TBI (NCT02367274)
- Testing
- BrainScope Ahead 200
- Where
- 11 sites in United States
- Volunteers
- 421 people
- Sponsor
- BrainScope Company, Inc.
Chronic Disease, Pain
Conversion to Embeda With Rescue Trial
The purpose of the research study is to find out if opioid dependent chronic pain patients who are judged by their physician to be eligible to change their current opioid medicine and to participate in this study can be…
- Trial name
- ConvERT (NCT01179191)
- Testing
- morphine sulfate and naltrexone hydrochloride (EMBEDA)
- Where
- 166 sites in United States
- Volunteers
- 684 people
- Sponsor
- Pfizer
Hepatitis C, Liver Cirrhosis
Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)
This is a Phase 3b, randomized, open-label, parallel-group, multi-center, multi-national study of low-dose maintenance Peg interferon alpha-2b (Peg-Intron®) in subjects with human immunodeficiency virus-hepatitis C virus…
- Conditions
- Hepatitis C, Liver Cirrhosis, HIV Infections
- Trial name
- NCT00381017
- Testing
- Peg interferon alpha-2b
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
Study In Asthma Control
This study will compare patients treated with a marketed medication and those who continue with their usual care to assess the proportion of patients achieving well controlled asthma after 24 weeks.
- Trial name
- NCT00273026
- Testing
- salmeterol xinafoate/fluticasone propionate
- Where
- 132 sites in Canada
- Volunteers
- 680 people
- Sponsor
- GlaxoSmithKline
Mitochondrial Diseases
EPI-743 for Mitochondrial Respiratory Chain Diseases
This study will evaluate the safety and efficacy of EPI-743 in participants with severe mitochondrial respiratory chain diseases who are considered to be within 90 days of end-of-life care.
- Trial name
- NCT01370447
- Testing
- EPI-743
- Where
- 16 sites in United States
- Sponsor
- PTC Therapeutics
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care
The primary objective of this post-marketing observational study was to obtain data on the characteristics (patient age/gender; disease type, severity and duration; disease specific treatment history; current concomitant…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT01163916
- Where
- 43 sites in Russia
- Volunteers
- 252 people
- Sponsor
- Abbott